26 LANDSDOWNE STREET, CAMBRIDGE, MA
Announce Merger Agreement to Advance Next-Generation Migraine Therapies, Investor Presentation
Departure of Greg Tourangeau; Alan Musso Appointed Principal Accounting Officer
Stockholders Elect Sonja Banks, Alan Ezekowitz, and Colin Hill as Directors
Changes in Board, Management or Compensation
Material disclosure
Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
Annual Report to Security Holders
Announces Recent Business Highlights and Financial Results for First Quarter 2026
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus Filed Pursuant to Rule 425
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Definitive Revised Proxy Statement